{"id":196641,"name":"NOVARTIS, INC.","slug":"novartis-inc","state":"DC","description":"Multinational biopharmaceutical company","totalSpending":1450000,"filings":29,"yearlySpending":[{"year":2019,"income":150000},{"year":2020,"income":200000},{"year":2021,"income":200000},{"year":2022,"income":350000},{"year":2023,"income":200000},{"year":2024,"income":200000},{"year":2025,"income":150000}],"firms":["FORBES-TATE"],"lobbyists":["ZACHARY WILLIAMS","ELIZABETH GREER","JEFFREY FORBES","JEFFREY STRUNK","JEFFREY SADOSKY","DERRICK WHITE","EDWARD RENO","CYNTHIA BROWN","FRANCESCA MCCRARY","KRISTINA DUNKLIN","BARRETT THORNHILL","MICHAEL WILLIAMS"],"issues":["TRD","HCR","MMM","BUD","CPT","TAX",null],"sampleDescriptions":["Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), FY 2020 appropriations.","Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP).","Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to Medicare, Medicaid, Cell and Gene Therapies.","Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).","Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).","Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136); Issues related to drug pricing and Section 340B of the Public Health Service Act; Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings.","Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136); Issues related to H.R. 925 - The Heroes Act.","Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies;  Issues related to drug pricing and Section 340B of the Public Health Service Act; Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).","Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).","Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).","Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines.","Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues related to drug pricing and Section 340B of the Public Health Service Act; Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.","Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instruction to Committees.","Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.","Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.","Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022.","Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.","Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instruction to Committees.","Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.","Issues related to prescription drug pricing; issues related to World Trade Organization IP waiver; issues related to pharmaceutical intellectual property; issues related to international trade."],"years":[2019,2020,2021,2022,2023,2024,2025]}